Amarin Corp Plc (AMRN)

[ziploc_1]

From SA article..."The actual launch of the product took place in Q4 2023. However, the issue of reimbursement of the drug by the government remains open and on this point, it is expected that the process will not be defined before the end of 2025."...

I disagree...The Chinese national health system has had Vascepa under study since before Q4 2023...Medical journals have been reporting on the superior efficacy and safety benefits of Vascepa...The data on Vascepa has been under review since Q4 2023 and probably even prior to that time...Recent articles have informed scientists and doctors the about the positive effects of Vascepa for patients...I would not be surprised to see a report of the approval of Vascepa for patients in mainland China released any time soon...followed by negotiations to be conducted by the Government health system and by Eddingpharm over reimbursements.